Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/11/8/1564 |
| _version_ | 1797439770977107968 |
|---|---|
| author | Zhenzhen Zhai Yanxin Huang Yawei Zhang Lili Zhao Wen Li |
| author_facet | Zhenzhen Zhai Yanxin Huang Yawei Zhang Lili Zhao Wen Li |
| author_sort | Zhenzhen Zhai |
| collection | DOAJ |
| description | Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, lupus erythematosus, and liver injury. |
| first_indexed | 2024-03-09T11:58:57Z |
| format | Article |
| id | doaj.art-bcafcafa02254e0c83cee8d9097f3683 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-09T11:58:57Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-bcafcafa02254e0c83cee8d9097f36832023-11-30T23:06:24ZengMDPI AGAntioxidants2076-39212022-08-01118156410.3390/antiox11081564Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related DiseasesZhenzhen Zhai0Yanxin Huang1Yawei Zhang2Lili Zhao3Wen Li4School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, ChinaStudies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, lupus erythematosus, and liver injury.https://www.mdpi.com/2076-3921/11/8/1564Nrf2clinical researchsmall molecule compoundsinflammation-related diseasesCOVID-19Alzheimer’s disease |
| spellingShingle | Zhenzhen Zhai Yanxin Huang Yawei Zhang Lili Zhao Wen Li Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases Antioxidants Nrf2 clinical research small molecule compounds inflammation-related diseases COVID-19 Alzheimer’s disease |
| title | Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases |
| title_full | Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases |
| title_fullStr | Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases |
| title_full_unstemmed | Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases |
| title_short | Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases |
| title_sort | clinical research progress of small molecule compounds targeting nrf2 for treating inflammation related diseases |
| topic | Nrf2 clinical research small molecule compounds inflammation-related diseases COVID-19 Alzheimer’s disease |
| url | https://www.mdpi.com/2076-3921/11/8/1564 |
| work_keys_str_mv | AT zhenzhenzhai clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases AT yanxinhuang clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases AT yaweizhang clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases AT lilizhao clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases AT wenli clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases |